Thus, in clinical practice, we only need to measure the expression values of two mRNAs (ANN and ARNTL2) in the tumor tissue of the patient to obtain the patient’s risk score, which in turn can predict the patient’s prognosis and response to immunotherapy. Here, BMAL2 is linked to neoplasm.